CA2975475A1 - Dimeric collagen hybridizing peptides and methods of using - Google Patents

Dimeric collagen hybridizing peptides and methods of using Download PDF

Info

Publication number
CA2975475A1
CA2975475A1 CA2975475A CA2975475A CA2975475A1 CA 2975475 A1 CA2975475 A1 CA 2975475A1 CA 2975475 A CA2975475 A CA 2975475A CA 2975475 A CA2975475 A CA 2975475A CA 2975475 A1 CA2975475 A1 CA 2975475A1
Authority
CA
Canada
Prior art keywords
collagen
peptide
peptide conjugate
gly
hybridizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2975475A
Other languages
English (en)
French (fr)
Inventor
Julian KESSLER
S. Michael YU
Yang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA2975475A1 publication Critical patent/CA2975475A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
CA2975475A 2015-01-30 2016-01-29 Dimeric collagen hybridizing peptides and methods of using Abandoned CA2975475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562125756P 2015-01-30 2015-01-30
US62/125,756 2015-01-30
PCT/US2016/015816 WO2016123570A1 (en) 2015-01-30 2016-01-29 Dimeric collagen hybridizing peptides and methods of using

Publications (1)

Publication Number Publication Date
CA2975475A1 true CA2975475A1 (en) 2016-08-04

Family

ID=56544437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2975475A Abandoned CA2975475A1 (en) 2015-01-30 2016-01-29 Dimeric collagen hybridizing peptides and methods of using

Country Status (7)

Country Link
US (2) US10953104B2 (enExample)
EP (1) EP3250240A4 (enExample)
JP (2) JP6942051B2 (enExample)
CN (1) CN107530454B (enExample)
AU (1) AU2016211242A1 (enExample)
CA (1) CA2975475A1 (enExample)
WO (1) WO2016123570A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112940A1 (en) * 2015-10-23 2017-04-27 University Of Utah Research Foundation Modified Collagen Hybridizing Peptides And Uses Thereof
WO2018106273A1 (en) * 2016-12-06 2018-06-14 University Of Utah Research Foundation Collagen targeting nanofibers and nanosheets
CN111303249B (zh) * 2020-01-02 2020-12-18 兰州大学 一种特异性检测病变胶原蛋白的探针、制备方法及应用
US12269864B2 (en) 2020-01-03 2025-04-08 Emory University Self-assembling collagen-like polypeptides for applications and uses related thereto
CN111407727B (zh) * 2020-03-26 2021-03-23 浙江大学 哺乳动物雷帕霉素靶蛋白（mTOR）阻断剂在制备治疗钙化性肌腱病药物中的应用
US20220050116A1 (en) * 2020-06-15 2022-02-17 University Of Utah Research Foundation Dimeric collagen hybridizing peptides and methods of use thereof
CN111704663B (zh) * 2020-06-29 2021-09-28 江南大学 一种胶原蛋白水凝胶的制备方法
WO2023034903A1 (en) * 2021-09-01 2023-03-09 3Helix, Inc. Systems and methods for detecting fibrosis
JP2024537778A (ja) * 2021-10-07 2024-10-16 スリーヘリックス， インコーポレイテッド 生物学的に活性なコラーゲンハイブリダイズペプチド
CN116298316B (zh) * 2023-01-18 2024-08-30 中山大学附属第五医院 一种诱导胶原杂交肽保持单链胶原杂交能力的方法及应用
CN121039152A (zh) * 2023-03-02 2025-11-28 3螺旋有限公司 抗炎生物活性胶原蛋白杂交肽及其使用方法
CN116715753B (zh) * 2023-05-11 2024-03-19 中山大学附属第五医院 一种保持单链构象的类肽胶原杂交肽的制备方法与应用
AU2025230534A1 (en) * 2024-02-28 2026-07-23 The Fifth Affiliated Hospital of Sun Yat-Sen University Radiolabeled collagen hybridizing peptide and preparation method therefor and use thereof
WO2026055394A1 (en) * 2024-09-05 2026-03-12 3Helix, Inc. Collagen hybridization peptides having a modified c-terminal and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576419A (en) * 1993-06-30 1996-11-19 Regents Of The University Of Minnesota Mild solid-phase synthesis of aligned branched triple-helical peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US8283414B2 (en) * 2004-11-23 2012-10-09 The Johns Hopkins University Compositions comprising modified collagen and uses therefor
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
WO2007139914A2 (en) * 2006-05-26 2007-12-06 Wisconsin Alumni Research Foundation Collagen mimics
US8654699B2 (en) 2008-03-14 2014-02-18 Apple Inc. Distributed ARQ for wireless communication system
CA2723824C (en) * 2008-05-09 2022-12-06 Surmodics Pharmaceuticals, Inc. Biocompatible and biodegradable elastomeric polymers
US10426850B2 (en) * 2011-11-22 2019-10-01 The Johns Hopkins University Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use
JP2015091760A (ja) * 2012-01-23 2015-05-14 学校法人早稲田大学 コラーゲン様ペプチドからなる薬物担体

Also Published As

Publication number Publication date
CN107530454A (zh) 2018-01-02
EP3250240A4 (en) 2018-10-10
CN107530454B (zh) 2021-10-26
US10953104B2 (en) 2021-03-23
JP2021152004A (ja) 2021-09-30
AU2016211242A1 (en) 2017-08-17
JP2018508492A (ja) 2018-03-29
US20180000960A1 (en) 2018-01-04
US11684675B2 (en) 2023-06-27
WO2016123570A1 (en) 2016-08-04
US20210322559A1 (en) 2021-10-21
EP3250240A1 (en) 2017-12-06
JP6942051B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
US11684675B2 (en) Dimeric collagen hybridizing peptides and methods of using
JP4851939B2 (ja) 自己−集合性ペプチド両親媒性物質および増殖因子送達のための関連する方法
WO2018106273A1 (en) Collagen targeting nanofibers and nanosheets
CN105102470A (zh) 新型α4β7肽二聚体拮抗剂
JP2017501136A5 (enExample)
KR20170087913A (ko) 나노물질, 조성물, 합성, 및 어셈블리
CN104011065A (zh) 肽纳米粒子及其用途
CN110790822A (zh) 可模拟血小板衍生因子生物活性的多肽衍生物、纳米纤维及其应用
WO2014059384A2 (en) ICAM-1 TARGETING ELPs
US20170112940A1 (en) Modified Collagen Hybridizing Peptides And Uses Thereof
WO2019044894A1 (ja) コラーゲンへの結合活性を有する環状ペプチド
US9238010B2 (en) Vesicles and nanostructures from recombinant proteins
WO2010135277A2 (en) Cyclic-glur6 analogs, methods of treatment and use
US20220050116A1 (en) Dimeric collagen hybridizing peptides and methods of use thereof
CN107529533B (zh) 一类可自组装成水凝胶的pH敏感多肽及其作为装载药物材料的应用
JP2023523262A (ja) 新規な細胞透過性ペプチド及びその用途
EP4180446A1 (en) Cyclic peptide, peptide complex, and drug composition containing said cyclic peptide and/or said peptide complex
EP1131344B1 (en) Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
TW202321274A (zh) 人類運鐵蛋白受體結合肽
Lopez‐Silva et al. Antibody Labeling With FITC Facilitates Controlled Release From Peptide Hydrogels Bearing Fc‐Binding Motifs
CN113750248B (zh) 病理识别分子-药物偶合物及其应用
US12415834B2 (en) GhR-binding peptide and composition comprising same
TW202530243A (zh) 胜肽
CA2967943C (en) Nanomaterial compositions, synthesis, and assembly
WO2025064985A1 (en) Myc INHIBITOR PROTEINS AND USES THEREOF

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220419